News ASCO26: Revolution's 'grand slam' data in pancreatic cancer Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.
News ASCO26: Big win for Erleada in perioperative prostate cancer ASCO today brings good news for patients with localised prostate cancer, as early use of J&J's ARPI offers a 19 month increase in median survival.
News ASCO26: Ivonescimab improves survival in NSCLC Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.
News ASCO26: Lilly's Retevmo aces early-stage lung cancer trial Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.
Oncology ASCO26: AI supercharging gene-based cancer detection, with D... Pharmaphorum caught up with Caris Life Science's David Spetzler to talk about how agentic AI is empowering whole genome sequencing in cancer detection
News ASCO26: BMS hails "compelling" phase 3 celmod readout Bristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods.
News UK offers meningitis jab to young people after outbreak The UK government has responded to calls to broaden vaccinations for meningitis B, offering the jab to "thousands" of young people this summer.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
